ALK and lung carcinoma: A retrospective study of patients with ALK fusion gene-positive lung cancer demonstrated a significantly higher VTE incidence among 422 patients with ALK fusion gene-positive lung cancer than that in patients who were negative for the fusion gene (42.7% vs. 28.6%, p < 0.0001) [27].